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Introduction
Alcohol abuse leading to alcoholic liver disease (ALD) is one 
of the most important causes of preventable morbidity and 
mortality in the world. Alcohol abuse is responsible for about 
50% cases of liver cirrhosis.[1,2] As a consequence, alcoholic 
cirrhosis is one of the most common indications for liver 
transplantation in Europe and in North America.[3,4]
ALD is a spectrum that ranges from fatty liver to alcoholic 
steatohepatitis (ASH) and eventually cirrhosis. Simple hepatic 
steatosis	is	the	most	common	histological	finding	and	occurs	
in 90% of heavy drinkers but is rapidly reversible with 
abstinence. Alcoholic hepatitis or ASH occurs in up to 35% of 
heavy drinkers and is usually a precursor of cirrhosis.[5] ASH 
is a clinico-pathological syndrome that denotes hepatocellular 
necrosis	and	inflammation.	Pathologic	characteristics	include	
development of Mallory “alcoholic” hyaline, prominent 
intra-sinusoidal collagen deposition and infiltration with 
polymorphonuclear leukocytes of the hepatic parenchyma, 
usually at the peri-venular area. However histologically, the 
majority of patients with severe alcoholic hepatitis have either 
significant	fibrosis	or	cirrhosis	of	the	liver.	Hence	alcoholic	
hepatitis is often superimposed on chronic liver disease and 
is one of the most important causes of acute on chronic liver 
failure.[6]
The pathogenesis of liver injury in acute alcoholic hepatitis 
remains elusive. Genetic factors and immune-mediated 
mechanisms have been postulated along with a direct 
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hepatotoxic effect of alcohol.[7] Impaired immune response, 
endoplasmic reticulum stress, mitochondrial dysfunction and 
free-radical injury induced by alcohol and its acetaldehyde 
adduct metabolites, Kupffer cell activation and cytokine 
production, have important roles in accentuating the hepatocyte 
injury and disease precipitation.[8,9] Studies have shown a linear 
relationship between tumor necrosis factor-alpha (TNF-α) 
receptors and mortality from acute alcoholic hepatitis.[10]
Glucocorticosteroids represent the most widely accepted 
but yet the most debatable therapy in patients with severe 
ALD. Corticosteroids have been shown to reduce cytokine 
production, suppress the formation of acetaldehyde adduct 
metabolites and neo-antigens and inhibit the production of 
collagen.[11] However down-regulation of steroid sensitivity, 
risk of infection and a rational therapeutic strategy of 
corticosteroids are all crucial aspects that need evaluation.
Pentoxifylline (PTX), a non-specific phosphodiesterase 
inhibitor with anti-inflammatory (TNF-α inhibition) and 
anti-fibrogenic properties, has been found to be useful 
in patients with acute alcoholic hepatitis with maddrey 
discriminant	 function	 (MDF)	 score	 ≥32.[12,13] Studies have 
shown	 that	 it	 also	 has	 a	 significant	 role	 in	 decreasing	 the	
risk of developing hepatorenal syndrome.[14,15]	The	beneficial	
effects are believed to occur through down regulation of 
TNF-α, interleukin (IL)-1, IL-6, transforming factor-beta, 
interferon-gamma, stellate cell activation and procollagen I 
messenger ribonucleic acid (mRNA) expression.[16]
Prednisolone and PTX have been shown to be individually 
useful	in	severe	alcoholic	hepatitis	with	DF	score	≥32.[14,17] A 
previous trial performed by our team had shown some evidence 
that PTX is probably superior to prednisolone alone.[15] 
However	the	efficacy	of	PTX	and	Prednisolone	combination	
over PTX alone in the management of acute alcoholic 
hepatitis	 (MDF	 score	≥32)	 is	 yet	 unrevealed.	The	 present	
study was initiated to probe into this issue and to measure 
the short and intermediate term outcomes of such therapeutic 
interventions.
Subjects and Methods
Totally 124 chronic alcoholic patients attending the liver 
clinic, outpatient department or emergency medical services 
of the Medical College and Hospital, Kolkata, were initially 
considered. The duration of the study was from January 2010 
to August 2012. Patients were initially examined clinically, 
evaluated and subsequently were admitted for the duration of 
the study. The study protocol was approved by the institutional 
ethical committee. All the patients underwent investigations 
for liver chemistry (liver function test, prothrombin time), 
complete hemogram, random blood sugar, urea, creatinine, 
electrolytes, viral markers such as hepatitis B surface 
antigen, anti-hepatitis C virus antibody, hepatitis A virus 
immunoglobulin M (IgM), hepatitis E virus IgM, serum 
ceruloplasmin, 24-h urinary copper (as and when required), 
anti‑human	 immunodeficiency	virus	 (HIV)	 antibody,	 chest	
X-ray, antinuclear antibody, upper gastrointestinal (G.I.) 
endoscopy and Doppler abdominal ultrasound (as and when 
required). Patients who had a history of chronic alcohol intake 
of more than 50 g/day with clinical and biochemical features 
of	severe	alcoholic	hepatitis	(MDF	score	≥32	and	Aspartate	
aminotransferase [AST]: Alanine aminotransferase [ALT] >2:1 
with absolute value of AST < 500 I.U/L and ALT < 200 IU/L) 
were included.
Patients with any other potential etiology of liver injury 
(acute or chronic viral hepatitis, autoimmune liver disease, 
Wilson’s disease) even in the background of chronic alcohol 
intake were excluded from the study. Furthermore patients 
who were positive for HIV antibodies or patients with a history 
of abstinence from alcohol in the last month were excluded. 
Patients with infection, sepsis or spontaneous bacterial 
peritonitis, acute pancreatitis, G.I. bleeding, hepatorenal 
syndrome or any other severe associated disease such as 
uncontrolled diabetes mellitus, systemic hypertension, heart 
failure, pulmonary disease or malignancy at the time of 
inclusion or in the previous 3 months were also excluded.
Model for end-stage liver disease (MELD) score and Glasgow 
alcoholic hepatitis score (GAHS) and Child-Pugh score were 
calculated for all patients who were included in the study. Only 
those patients who gave a prior informed written consent for 
pharmacotherapy	were	considered	for	the	final	study.
The recruited patients were then divided into 2 groups by a 
computer generated randomization table. Group 1: Patients 
receiving PTX only. Group 2: Patients receiving PTX plus 
prednisolone. Now the pharmacotherapy was started within 
a week of admission.
Patients	 in	Group	 1	 received	PTX	 (Trental	 tablets,	 sanofi	
Aventis, Mumbai, India) at a dose of 400 mg thrice daily 
orally and a placebo tablet in the place of prednisolone for 
the	first	4	weeks.
Patients in Group 2 received prednisolone tablet (Wysolone, 
Wreath, Mumbai, India) at a dose of 40 mg once daily for 
4 weeks and PTX tablets at a dose of 400 mg thrice daily for 
the same duration.
During the study concomitant treatment with salicylates, 
non‑steroidal	anti‑inflammatory	drugs,	budesonide,	anti‑TNF‑α 
agents, Vitamin E, s-adenosyl methionine or ursodeoxycholic 
acid were not allowed. The investigator, who allocated the 
patients to the groups, administered the drugs and collected 
the clinical and laboratory data, as well as statisticians were 
all blinded regarding the nature of the pharmacotherapy. All 
the patients were admitted in the wards of the Department 
of Medicine, Medical College and Hospital, Kolkata for the 
initial period of 4 weeks. All investigations such as liver 
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Results
A total number of 124 patients were initially evaluated. 
Out	of	them,	64	patients	who	fulfilled	the	inclusion	criteria	
without any other potential etiology of liver injury or severe 
co-morbid states were considered. One patient refused to 
give consent for the study and another one refused admission. 
62	patients	who	fulfilled	the	inclusion	and	exclusion	criteria	
and who gave informed written consent were randomized and 
divided into 2 groups. Group 1 (PTX only) had 31 patients 
while Group 2 (PTX plus Prednisolone) had 31 patients. The 
total duration of follow-up was 12 months, with the patients 
being examined and evaluated in the liver clinic on a monthly 
basis. One patient in Group 1 developed severe vertigo within 
7 days after starting PTX and one patient in Group 2 withdrew 
voluntarily from the study and hence they were excluded. 
Hence, a total of 60 patients, 30 in each group, were considered 
for	the	final	analysis.
The baseline parameters (clinical and biochemical) of the total 
60 patients, 30 in each group were comparable and shown in 
Table 1.
In Group – 1, 6 patients expired at the end of 1 year. Out of the 
6	patients	lost,	three	patients	succumbed	in	the	first	4	weeks;	
two expired between 4 weeks to 3 months of therapy, while one 
expired between 3 months to 1 year of therapy. PTX therapy 
was stopped prematurely (i.e., within 3 months) in 5 patients 
because of the development of life-threatening complications, 
all of them died. Out of 5 patients, 3 patients expired following 
massive (GI) bleeding, 1 patient was lost of progressive hepatic 
encephalopathy and 1 patient died of sepsis, not responding to 
conservative	management	including	antibiotics,	fluid	therapy	
etc., 1 patient died of GI bleeding after 3 months of therapy.
function	tests,	prothrombin	time,	electrolytes,	renal	profile	and	
abdominal ultrasound were repeated after the initial 4 weeks 
of pharmacotherapy.
After the initial 4 weeks, the study was opened and the 
patients allocated to different groups were revealed. Patients 
in Group 1 (PTX) who tolerated the drug well, continued to 
receive the medication at the same dose for the next 8 weeks 
and then stopped. After 4 weeks of initial therapy, the dose 
of prednisolone in Group 2 was tapered by 5 mg/week over 
a period of 7 weeks and then stopped and received PTX like 
Group 1 patients. Only those patients who were clinically stable 
at the end of 4 weeks were discharged and later followed-up 
in the liver clinic. All the patients were counseled for strict 
alcohol abstinence at the time of discharge from the hospital.
The patients were reviewed at least once a month in the liver 
clinic. During follow-up, all the patients were examined 
clinically and asked about drug compliance, intake of 
alcohol or potential drug adverse effects. Liver function 
tests, prothrombin time, renal function test, electrolytes and 
abdominal ultrasounds were performed as and when required. 
MDF, MELD, GAHS and Child-Pugh scores were calculated 
for all the patients during follow-up.
Statistical analysis
Student’s t-test was used for analysis of continuous variables. 
Chi-square test was used for categorical variables. All results 
of continuous variables were expressed as mean (SD). Survival 
curves were estimated according to the Kaplan-Meier method 
and were compared using the log-rank test. Results were 
considered	statistically	significant	at P <	0.05.	 	SPSS	statistics	
version 17.0 (developer IBM)  software was used for statistical 
analysis.
Table 1: Comparison of base line parameters of patients receiving PTX (Group 1) versus those receiving PTX plus 
prednisolone (Group 2) in the treatment of severe alcoholic hepatitis (mean [SD])
Parameter Group 1 (PTX) (n=30) Group 2 (PTX+prednisolone) (n=30) P
Age (year) 41.33 (7.81) 42.73 (0.43) 0.55
Male: Female 30:0 30:0 ‑
Ascites 27 28 0.64
Hepatic encephalopathy 10 11 0.79
Varices 26 25 0.72
Maddrey DF score 56.62 (37.57) 63.14 (30.98) 0.46
MELD score 20.13 (4.47) 20.9 (3.34) 0.45
GAHS 7.7 (1.12) 7.87 (0.9) 0.53
Child’s score 11.33 (1.47) 11.90 (1.15) 0.10
Urea (mg/dL) 31.57 (14.30) 27.60 (8.65) 0.20
Creatinine (mg/dL) 1.038 (0.19) 1.013 (0.21) 0.64
Bilirubin (mg/dL) 4.76 (3.72) 4.67 (1.87) 0.91
Albumin (g/dL) 2.85 (0.57) 2.9 (0.63) 0.75
AST (IU/L) 117.67 (49.55) 120.40 (31.22) 0.80
ALT (IU/L) 42.03 (18.84) 48.09 (11.93) 0.09
INR 2.07 (0.81) 2.11 (0.52) 0.83
AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, PTX: Pentoxifylline, SD: Standard deviation, DF: Discriminant function, MELD: Model for end-stage liver disease, GAHS: Glasgow 
alcoholic hepatitis score, INR: International normalized ratio
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The	morbidity/complication	profiles	among	 the	 two	groups	
were comparable [Table 2]. Nausea followed by vomiting and 
dyspepsia were the most common adverse effects encountered 
in both groups. Patients receiving PTX complained of nausea 
and vomiting more frequently, whereas dyspepsia was more 
common among those receiving PTX plus prednisolone. Within 
a week after initiation of PTX, 2 patients from PTX group and 
1 patient from PTX plus prednisolone group also developed 
mild vertigo which subsided spontaneously within few days. 
Oral thrush, impaired glucose tolerance, poor wound healing 
were	some	of	the	significant	problems	faced	by	the	patients	
in the PTX plus prednisolone group.
Table	3	shows	the	baseline	profile	of	patients	who	succumbed	
to various complications, as compared to those surviving 
at the end of the study (i.e., 1 year). It shows that baseline 
MDF, MELD, GAHS, Child-Pugh score and International 
Normalized	Ratio	 (INR)	were	 significantly	 higher	 among	
patients who succumbed to the disease as compared to those 
who survived [P < 0.001, Table 3]. It also shows that baseline 
albumin	was	significantly	lower	among	patients	who	expired	
as compared to those who survived [P < 0.01, Table 3].
Table 4 shows the progression of MDF, MELD, Child-Pugh 
and GAHS score in patients over 12 months. MDF score and 
MELD	score	were	observed	to	be	significantly	lower	among	
patients receiving PTX at the end of 4 week, as compared to 
those receiving PTX plus prednisolone (P < 0.05 and < 0.01 
respectively).	But	 there	were	 no	 significant	 differences	 in	
MELD, MDF, Child-Pugh and GAHS score between two 
groups at the end of 3 months, 6 months and 1 year.
Discussion
More than 17 controlled trials and at least 13 meta-analyses 
have reported the effects of corticosteroids in the treatment of 
Figure 2: Survival curves (Kaplan‑Meier life table analysis) of patients 
receiving pentoxifylline (PTX) (Group – 1) as compared to patients 
receiving PTX plus prednisolone (Group – 2), at the end of 1 year of 
therapy
In Group – 2, 10 patients expired at the end of 1 year out of 
these	10	patients,	1	succumbed	in	the	first	4	weeks,	8	more	
were lost between 4 weeks to 3 months of therapy while 1 more 
was lost between 3 months and 1 year of therapy. PTX plus 
prednisolone therapy was stopped prematurely (i.e., within 
3 months) in 9 patients due to development of life-threatening 
complications. Out of these 9 patients, 3 patients developed 
sepsis and all of them died of septic shock despite of adequate 
antibiotics and hemodynamic support, 1 patient was lost of 
progressive hepatic encephalopathy, 2 patients had upper GI 
bleeding and succumbed to hemodynamic failure, 3 patients 
died of hepatorenal syndrome, not responding to conservative 
management. This was in sharp contrast to Group – 1, in which 
none of the patients developed hepatorenal syndrome. 1 patient 
died of GI bleeding after 3 months of therapy.
Although, the survival probability was higher among patient 
receiving only PTX (83.3% [25/30] at the end of 3 months 
and 80% [24/30] at the end of 1 year) when compared to those 
receiving PTX plus prednisolone (70% [21/30] at the end of 
3 months and 66.7% [20/30] at the end of 1 year), P values 
were	not	statistically	significant	as	elaborated	in	Kaplan‑Meier	
analysis shown in Figures 1 and 2 (P = 0.37 at 3 months and 
P = 0.32 at 1 year, Log rank test).
Twenty seven patients in Group 1 and 29 patients in 
Group 2 were evaluated in the liver clinic at the end of 
4 weeks. The study was opened at this point in time and the 
allotment of patients to the different groups was revealed. 
The investigation done at baseline were repeated and the 
patients were re-admitted if deemed necessary. The patients 
were followed-up on a monthly basis and the investigations 
were repeated at the end of 3 months, 6 months and 1 year. 
Although the patients did relatively well beyond 3 months of 
follow-up, only 1 more patient from each group succumbed 
to the disease.
Figure 1: Survival curves (Kaplan‑Meier life table analysis) of patients 
receiving pentoxifylline (PTX) (Group – 1) as compared to patients 
receiving PTX plus prednisolone (Group – 2), at the end of 3 months 
of therapy
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ALD	in	the	past	40	years	with	conflicting	results.	However	
current guidelines of the American College of Gastroenterology 
recommend the use of glucocorticosteroids in the treatment 
of	patients	with	severe	alcoholic	hepatitis	as	defined	by	the	
Maddrey	score	(DF	≥	32).[18,19]
PTX, a non-specific phosphodiesterase inhibitor, with 
combined anti-inflammatory and anti-fibrotic properties, 
has also emerged as an alternative therapeutic approach. 
The	beneficial	effects	are	believed	to	occur	through	various	
mechanisms such as inhibition of phosphodiesterases, 
increased cAMP level and down regulation of TNF-α, IL-1, 
IL-6, TGF-β, interferon-gamma, stellate cell activation and 
pro-collagen I mRNA expression.[16] It has been shown to block 
the activation of hepatic stellate cells in culture.[20]
The use of (PTX) in the treatment of severe alcoholic 
hepatitis has been supported by Akriviadis et al.[14] in a 
double-blind placebo-controlled trial, which showed that 24% 




Although favorable results of (PTX) used in the treatment of 
severe	alcoholic	hepatitis	patients	with	a	MDF	score	≥32	have	
been previously reported, it is not currently recommended as 
a	first	line	treatment	for	alcoholic	hepatitis	owing	to	lack	of	
evidence	for	its	efficacy	as	compared	to	the	standard	treatment	
with corticosteroids. In a very recent issue of World Journal 
of Gastroenterology,[15]	our	team	compared	for	the	first	time	
the two treatment modalities head to head in a randomized 
controlled study, demonstrating the advantage of PTX over 
corticosteroids	in	terms	of	patients’	survival	and	risk‑benefit	
profile.	Prevention	of	Hepatorenal	syndrome	may	account	for	
the survival advantage of PTX over corticosteroids in patients 
with severe alcoholic hepatitis.
In	 the	present	study,	we	compared	 the	efficacy	of	combining	
PTX to prednisolone over PTX alone. The group receiving PTX 
and prednisolone had no additional improvement in survival. 
There was a trend toward reduced survival in the combination 
group (70% at the end of 3 months and 66.7% at the end of 
1 year) when compared to those receiving only PTX (83.3% 
at the end of 3 months and 80% at the end of 1 year), although 
statistically	non‑significant.	This	increased	mortality	in	PTX	plus	
prednisolone group may be explained by the complications of 
steroids such as sepsis, GI. bleeding. MDF score in PTX group 
was	 significantly	 lower	 than	PTX	plus	 prednisolone	group	
at the end of 28 days of therapy (34.89 [8.29] in Group 1 vs. 
43.53 [20.19] in Group 2, P = 0.04). MELD score in the PTX 
group	was	also	significantly	lower	than	PTX	plus	prednisolone	
group at the end of 28 days of therapy (15.26 [2.22] in Group 1 vs. 
18.76 [5.70] in Group 2, P = 0.004). So combination of PTX and 
prednisolone therapy was no way superior to PTX alone.
One study suggested that patients with a MDF score >54 were at 
a higher mortality risk from use of steroids than from not being 
treated.[21] In our study, only 1 patient survived among 9 patients 
with MDF score >70, those who received PTX plus prednisolone.
Three patients in the PTX plus prednisolone group died due 
to hepatorenal syndrome but none died of this complication 
in the PTX group. In spite of increased occurrence of nausea 
and to a lesser extent vomiting, among patients in the PTX 
group, they were not severe enough to warrant termination of 
therapy. Within a week after initiation of PTX, 2 patients from 
PTX group and 1 patient from PTX plus prednisolone group 
developed mild vertigo which subsided spontaneously within 
few days. Oral thrush, impaired glucose tolerance, poor wound 
healing	were	some	of	the	significant	problems	faced	by	the	
patients in the PTX plus prednisolone group.
Retrospectively, on analyzing different liver function scores at 
the time of inclusion, higher MDF, MELD, GASH, Child-Pugh 
Table 2: Morbidity/complications profile of patients receiving PTX (Group 1) or PTX plus prednisolone (Group 2) in the 
treatment of severe alcoholic hepatitis
Complications Duration of follow‑up
0‑3 months 3 months‑1 year
Group 1 (n=30) Group 2 (n=30) Group 1 (n=25) Group 2 (n=21)
Nausea 20 16 10 3
Vomiting 10 7 3 1
Dyspepesia 3 8 1 1
Oral thrush ‑ 6 ‑ ‑
G.I. bleed 3 2 1 1
Sepsis 1 3 ‑ 2
Recurrent encephalopathy 1 5 ‑ ‑
Worsening ascites ‑ 1 ‑ 1
Impaired glucose tolerance ‑ 2 ‑ 1
Delayed wound healing ‑ 1 ‑ 1
Hepatorenal syndrome ‑ 3 ‑ ‑
Vertigo 2 1 ‑ ‑
PTX: Pentoxifylline, G.I.: Gastrointestinal
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score, INR and low albumin level were associated with the 
occurrence of increased mortality among patients with severe 
alcoholic hepatitis.
Limitation of our study is inability to document histological 
changes in two groups of patients because of unavailability of 
transjugular liver biopsy in our hospital.
So	no	therapeutic	advantage	or	mortality	benefit	was	observed	
by combining PTX with prednisolone. However, further studies 
with	a	larger	cohort	of	patients	are	needed	to	confirm	our	findings.
Conclusion
ALD is a major global health burden and newer horizons in 
the treatment will help better medical control of this disease 
entity. PTX being one such important molecule has emerged 
with a promising role. Our present study thus reveals a very 
important observation that combining these two modalities 
yields	no	additional	benefit	in	terms	of	mortality	and	morbidity	
from that of PTX monotherapy.
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PTX: Pentoxifylline, DF: Discriminant function, MELD: Model for end-stage liver disease, GAHS: Glasgow alcoholic hepatitis score
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